Navigation Links
Forest Laboratories' Lexapro and Generics-Dominated Fluoxetine Lead First-Line Therapy in the Treatment for Major Depression

Doctors Disagree Over Which Drugs Are More Effective, According to a New

Report from Decision Resources

WALTHAM, Mass., Oct. 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Forest Laboratories' Lexapro and generics- dominated fluoxetine lead first-line therapy in the treatment of major depression. According to the new report entitled Treatment Algorithms in Major Depression, selective serotonin reuptake inhibitors (SSRIs), which include Lexapro and Prozac, account for 63.6 percent of patients on first-line therapy. Surveyed physicians indicate the reasons for SSRIs being so heavily used are efficacy, cost and physician familiarity. Eighty percent of surveyed psychiatrists and seventy percent of surveyed primary-care physicians (PCPs) said the reason why they chose SSRIs over benzodiazepines is efficacy. The major reason 49 percent of surveyed psychiatrists chose SSRIs over serotonin/norepinephrine reuptake inhibitors (SNRIs) is cost, while 49 percent of PCPs say they chose SSRIs over SNRIs owing to familiarity with the former class.

The report also finds that psychiatrists and PCPs do not all agree on what the most effective drugs are for treatment of major depression; therefore there is significant variation in the choice of agents, with no clear dominant player. Forty four percent of surveyed PCPs say SSRIs are more effective than SNRIs, but 72 percent of psychiatrists believe the opposite. Sixty two percent of surveyed PCPs think Lexapro's efficacy against depression is a major reason to choose it, but only 24 percent of surveyed psychiatrists agree.

"We project a significant increase in the use of SNRIs in first-line therapy in the next two years," said Michael Malecki, Ph.D., analyst at Decision Resources. "Forty five percent of surveyed psychiatrists and forty eight percent of surveyed PCPs say they will more frequently prescribe SNRIs in first line. We believe that generic forms of Wyeth's Effexor XR will help make SNRIs more cost effective, thus driving the use of this class in early therapy."

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

For each disease examined, Decision Resources' Treatment Algorithms Insight Series provides:

-- Summary of U.S. medical practice based on interviews with leading

experts in the field

-- Qualitative diagnosis/referral/treatment algorithm for the United


-- Drug usage by lines of therapy (1st, 2nd, 3rd line)

-- Discussion of key freeform combinations by lines of therapy

-- Product share (class and specific compound level) within each line of

therapy (1st, 2nd, 3rd line)

-- Progression of therapy from key 1st line products

-- Pathway to key therapies from previous therapies

-- Qualitative analysis of 2-year forecast incorporating upcoming

launches, changes in reimbursement, etc.

About Decision Resources

Decision Resources, Inc., ( ) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.


SOURCE Decision Resources
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. DeForest biodiesel plant begins production
2. Biodiesel plant being built in DeForest to make alternative fuel
3. Use of X-rays to advance wood-decay knowledge leads to honor for Forest Products Lab biologist
4. Biodiversity threatened as forests become islands of green, UW professor says
5. BioRobot MDx standardize your automated protocols in clinical laboratories
6. Distance-Learning Remote Laboratories using LabVIEW
7. States are the best laboratories for healthcare reform
8. Scientific Protein Laboratories Acquired by New York firm
9. The Genesis of Gendicine: The Story Behind the First Gene Therapy
10. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
11. TomoTherapy opens technical training center
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... The Academy of Model Aeronautics (AMA), ... MultiGP, also known as Multirotor Grand Prix, to represent the First–Person View (FPV) racing ... AMA members have embraced this type of racing and several new model aviation pilots ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris ... today that the remaining 11,000 post-share consolidation (or ... Warrants (the "Series B Warrants") subject to the ... on November 23, 2015, which will result in ... giving effect to the issuance of such shares, ...
(Date:11/24/2015)... ... November 24, 2015 , ... Creation ... on being named to Deloitte's 2015 Technology Fast 500 list of the fastest ... AcceleDent®, a FDA-cleared, Class II medical device that speeds up orthodontic tooth movement ...
(Date:11/24/2015)... Nev. , Nov. 24, 2015  PDL BioPharma, Inc. ... P. McLaughlin , the company,s president and chief executive officer, ... Healthcare Conference next week in New York City ... occur on Tuesday, December 1, 2015 at 9:30 a.m. EST. ... Please connect to the website at least 15 minutes prior ...
Breaking Biology Technology:
(Date:10/29/2015)... Oct. 29, 2015  The J. Craig Venter Institute ... "DNA Synthesis and Biosecurity: Lessons Learned and Options for ... Health and Human Services guidance for synthetic biology providers ... --> --> Synthetic ... the potential to pose unique biosecurity threats. It now ...
(Date:10/29/2015)... October 29, 2015 NXTD ... company focused on the growing mobile commerce market ... that StackCommerce, a leading marketplace to discover and ... Wocket® smart wallet on StackSocial for this holiday ... or the "Company"), a biometric authentication company focused ...
(Date:10/27/2015)... , Oct. 27, 2015 Synaptics Inc. (NASDAQ: ... today announced that Google has adopted the Synaptics ® ... controller solutions to power its newest flagship smartphones, the ... Huawei. --> --> ... Google to provide strategic collaboration in the joint development ...
Breaking Biology News(10 mins):